Newly Diagnosed With AML: First Steps

AML is a group of blood cancers in which immature myeloid cells, called blasts, multiply in the marrow. As they crowd it, the body runs short of healthy white cells, red cells, and platelets. That is why weakness, fever, infection, pallor, and bleeding are the usual first signs. NCI notes these symptoms often build over about 4 to 6 weeks before anyone names the cause.

The diagnosis needs 20 percent or more blasts in the blood or marrow. Four genetic findings are exceptions to that rule: t(15;17), t(8;21), inv(16), and t(16;16). Flow cytometry is the main tool for telling AML apart from other leukemias. A marrow biopsy supplies material for chromosome and gene testing.

The American Cancer Society projects 22,720 new US cases and 11,500 deaths for 2026, and SEER republishes that projection. NCI's own SEER measurements give a median age at diagnosis of 70 and five-year relative survival of 33.4 percent, based on people diagnosed between 2016 and 2022.

Acute promyelocytic leukemia, or APL, is defined by a fusion protein called PML::RARA. It makes up 5 to 8 percent of AML cases.

APL matters urgently for one reason. It is commonly linked to disseminated intravascular coagulation, a clotting failure that causes bleeding. NCI lists bleeding, differentiation syndrome, and infection as the causes of early death in APL.

The treatment is also different. NCI describes all-trans retinoic acid, also called ATRA or tretinoin, which pushes the leukemia cells to mature. Low- to intermediate-risk APL means a white cell count of 10 x 10^9/L or under. That group is given ATRA with arsenic trioxide and no chemotherapy. Higher-risk APL gets ATRA with chemotherapy. The arsenic trioxide label carries a boxed warning. It covers differentiation syndrome, heart rhythm changes, and brain injury. Tretinoin has its own boxed warning for harm in pregnancy and for differentiation syndrome. That syndrome affected about 26 percent of people in its label.

About half of people with AML have a chromosome abnormality. NCI calls chromosome analysis mandatory here. Testing for changes in NPM1, FLT3, CEBPA, RUNX1 and other genes is now routine too. Together these give the strongest guide to how treatment will go.

NCI also lists things that count against a good result:

• Older age at diagnosis.
• Leukemia found in the brain or spinal cord.
• An active infection when AML is found.
• A white cell count above 100,000 per cubic millimetre.
• AML that followed earlier chemotherapy or radiation.
• A history of myelodysplastic syndrome.

The classic regimen is seven days of cytarabine by continuous infusion with three days of an anthracycline. It is usually called 7 + 3, and it produces complete remission in roughly 65 percent of people.

Two drugs get added in specific situations. Midostaurin is approved with induction when AML carries any FLT3 variant. In its trial, median survival was 75 months with it and 26 months without. Gemtuzumab ozogamicin is the other. Its label carries a boxed warning about liver injury, including a severe or fatal blockage of the small liver veins.

There is also a liposomal form of daunorubicin and cytarabine. It is for people aged 60 to 75 whose AML followed earlier treatment or grew out of myelodysplasia. It raised median survival from 5.95 months to 9.56 months.

Not everyone should have intensive chemotherapy. For older adults who decline 7 + 3, NCI treats low-dose cytarabine, decitabine, azacitidine, and supportive care alone as reasonable choices. Venetoclax can be paired with one of the hypomethylating drugs or with low-dose cytarabine. That combination is approved for people aged 75 and over, and for anyone whose other health problems rule out 7 + 3. These gentler regimens carry on as long as they help, rather than ending after a set number of courses.

Treatment aims at complete remission because partial remission offers no real survival benefit. Roughly 60 to 70 percent of adults reach it after appropriate induction. For people under 60, the expected remission rate is above 65 percent.

More than a quarter of adults with AML survive three years or more and may be cured. That is about 45 percent of those who reach remission. Ask where you sit in that picture, and what would move you.

• Call 911 or go to an emergency department if a sudden severe headache, confusion, or one-sided weakness appears, or if you have chest pain, breathlessness at rest, or bleeding you cannot stop. In APL, bleeding is the leading cause of early death, so treat it as an emergency rather than something to report later.
• Call your leukemia team at once, day or night, if a thermometer reads 100.4°F (38°C) or more, or chills set in. In AML the marrow is already short of working white cells, and induction chemotherapy empties it further, so a fever is a medical emergency. If you cannot get through in minutes, go to an emergency department and say you are on chemotherapy for AML, so antibiotics are not delayed.
• Call your care team the same day if you have bleeding gums, nosebleeds, blood in the urine or stool, or bruises that appear without any knock.
• Call your care team the same day if anything new starts while you are on ATRA or arsenic trioxide, particularly breathlessness, swelling, or weight gain. These can be the opening signs of differentiation syndrome, which both labels carry a boxed warning about. A temperature on these drugs is not a same-day item: it belongs with the emergency bullet above, and you should ring at once whatever else is going on.
• Call your care team within a day or two if tiredness deepens sharply, you become short of breath climbing stairs, or you feel faint on standing.

Acute Myeloid Leukemia (AML), What Is Leukemia?, What Does Bone Marrow Involvement Mean?, and Leukemia Treatment by Type.

• https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
• https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
• https://seer.cancer.gov/statfacts/html/amyl.html
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=101fc347-d0ad-4aee-8b06-9feb187fd741
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=264138c1-9e5f-45ef-be87-79ca97c989d9
• https://www.cdc.gov/cancer-preventing-infections/patients/fever.html